Treatment of a elderly patient of myelodysplastic syndrome-ring sideroblastic refratory anemia with decitabine and review of literatures

VernacularTitle:地西他滨治疗老年难治性骨髓增生异常综合征-环形铁粒幼细胞性贫血一例并文献复习
Author: Jiying SU ; Qi HE ; Lingyun WU ; Chao XIAO ; Chunkang CHANG ; Xiao LI
Publication Type:Journal Article
Keywords: Anemia,sideroblastic; Decitabine; Cytogenetic relapse
From: Journal of Leukemia & Lymphoma 2010;19(10):610-612
CountryChina
Language:Chinese
Abstract: Objective To study the effect of decitabine treating elderly patient with myelodysplastic syndrome-ring sideroblastic refractory anemia (MDS-RAS) and review the literatures. Methods Decitabine treated a patient with MDS-RAS four courses, at the dose of 25 mg everyday for 5 days per course. Observed the change of symptoms, peripheral blood cell counts, myelogram, T cell polarization, cellular immunity,chromosome. Determined the curative effect combined with efficiency standard of WHO 2008. Results The clinical symptoms got better after two courses. Peripheral blood cell counts began to get better after one course. The number of leukocyte, hemoglobin and platelet got nearly normal after four courses. After two courses, T cell polarization state got normal, the number of iron ring promyelocyticin bone marrow declined from 16 % to 0 and chromosome changed from complex karyotype to normal. Conclusion Decitabine is an effective drug to the old patient with MDS-RAS. But it needs to increase the number of cases and follow up long-term to observe the effective rate and long-term efficacy.